1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
NIA invites applications for the Leadership Award for Alzheimer's Disease and Related Dementias Research (R35). Applicants will be supported to develop and implement innovative multidisciplinary research and mentoring programs through an interchange of ideas that enable individuals and their institutions to strengthen existing programs and the development of new research programs that are specific to the goals/milestones of the NIH Alzheimer's Disease and Alzheimer's Disease Related Dementias Summits.
Funding Opportunity Number: RFA-AG-21-007. Assistance Listing: 93.866. Funding Instrument: G. Category: HL.
Get alerted about grants like this
Get emailed when new opportunities from “National Institutes of Health” or related funders appear. Free, weekly, unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Eligible applicants: State governments; County governments; City or township governments; Special district governments; Independent school districts; Public and State controlled institutions of higher education; Native American tribal governments (Federally recognized); Public housing authorities / Indian housing authorities; Native American tribal organizations (other than Federally recognized); Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Private institutions of higher education; For-profit organizations other than small businesses; Small businesses; Others (see text field entitled Additional Information on Eligibility for clarification). Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed. Confirm the full requirements in the official notice before applying.
The published deadline was June 19, 2020, which has passed. Check the official notice for any future application windows before investing time in a proposal.
Yes — Leadership Award for Alzheimer's Disease and Related Dementias Research (R35 Clinical Trial Not Allowed) is offered by National Institutes of Health and this listing comes from Grants.gov, an official U.S. federal source. Federal applications generally require registrations (for example SAM.gov or an agency submission portal), so allow extra lead time.
This opportunity targets applicants in Alaska and Hawaii. Check the official notice for exact location requirements.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
Purpose. This Funding Opportunity Announcement (FOA) solicits Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to develop, enhance and validate translational tools to facilitate rigorous study of complementary and alternative medicine (CAM) approaches that are in wide use by the public. Recent data from the National Health Interview Survey [http://www.cdc.gov/nchs/nhis.htm] establish that Americans are utilizing CAM approaches to promote health and well-being, to treat or prevent disease, and for symptom relief. CAM approaches being widely used include massage and manipulative therapies, meditation, yoga, and acupuncture. Health conditions, particularly chronic pain, back pain and musculoskeletal pain, are the most commonly cited reasons for their use. This FOA focuses on encouraging the development of improved tools to study safety, efficacy, and clinical effectiveness of widely used CAM approaches, such as: mind-body interventions, manual therapies, yoga, and acupuncture. This FOA is not focused on tools for the study of natural products, such as herbal therapies. Mechanism of Support. This FOA will utilize the SBIR (R43/R44) grant mechanisms for Phase I, Phase II, and Fast-Track applications and runs in parallel with a FOA of identical scientific scope, RFA-AT-09-002, which solicits applications under the R01 grant mechanism. Funds Available and Anticipated Number of Awards. The estimated amount of funds available for support of 5 projects awarded as a result of this announcement is $1.25 million for fiscal year 2010. Future year amounts will depend on annual appropriations. Funding Opportunity Number: RFA-AT-09-004. Assistance Listing: 93.213. Funding Instrument: G. Category: HL. Award Amount: $1.3M total program funding.
-This Funding Opportunity Announcement (FOA) solicits Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) for the modification or development of new screening technologies that are better able to consistently detect mild hearing loss (i.e., less than 40 dB Hearing Level or 40 dB HL) in one or both ears in infants and young children without significantly increasing the number of false positives (i.e., those who fail the screen but do not have hearing loss). -The Early Hearing Detection and Intervention (EHDI) program within the National Center for Birth Defects and Developmental Disabilities (NCBDDD) of the Centers for Disease Control and Prevention (CDC) and the National Institute on Deafness and Other Communication Disorders (NIDCD), NIH, are working to ensure infants and children with mild forms of hearing loss are identified as soon as possible. Part of this effort involves having screening technology available that can reliably detect these hearing losses. -This FOA will utilize the SBIR (R43/R44) grant mechanisms for Phase I, Phase II, and Fast-Track applications and runs in parallel with a FOA of identical scientific scope, PA-06-547, that solicits applications under the Small Business Technology Transfer (STTR [R41/R42]) grant mechanisms. Note,that CDC does not accept STTR applications so is participating only in PA-06-546. Funding Opportunity Number: PA-06-546. Assistance Listing: 93.173,93.283. Funding Instrument: G. Category: HL.
Purpose. This funding opportunity announcement (FOA) solicits Small Business Innovation Research (SBIR) grant applications that propose to develop novel pharmacologic agents for brain research related to mental disorders, including research aimed at discovering new drugs for these disorders. In addition, this FOA solicits SBIR grant applications that propose to take existing, promising compounds through the next step of drug discovery and development. Finally, this FOA also encourages SBIR grant applications designed to study the effectiveness of novel interventions. Mechanism of Support. This FOA will utilize the SBIR (R43/R44) grant mechanisms for Phase I, Phase II, and Fast-Track applications. Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications. The total amount awarded and the number of awards will depend upon the quality, duration, and costs of the applications received. Budget and Project Period. Phase I awards normally may not exceed $100,000 total for a period normally not to exceed 6 months. Phase II awards normally may not exceed $750,000 total for a period normally not to exceed 2 years. However, for this funding opportunity, budgets up to $350,000 total costs per year and time periods up to two years for Phase I may be requested. Budgets up to $600,000 total costs per year and up to three years may be requested for Phase II. Eligible Institutions/Organizations: Only United States SBCs are eligible to receive SBIR applications. A SBC is one that, on the date of award for both Phase I and Phase II funding agreements, meets ALL of the criteria as described in Section III. Eligible Project Directors/Principal Investigators: Individuals with the skills, knowledge, and resources necessary to carry out the proposed research are invited to work with their organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support. On an SBIR application, the PD/PI must have his/her primary employment (more than 50%) with the SBC at the time of award and for the duration of the project. Number of Applications: Applicant SBCs may submit more than one application, provided each application is scientifically distinct. Resubmissions: Applicants may submit a resubmission application, but such application must include an Introduction addressing the previous peer review critique (Summary Statement). Number of PDs/PIs. More than one PD/PI, or multiple PDs/PIs, may be designated on the application. Funding Opportunity Number: PA-08-142. Assistance Listing: 93.242. Funding Instrument: G. Category: HL.
To increase research capacity for NF, the NFRP is offering the NFRA. The intent of the NFRA is to provide a framework of intensive mentoring and iterative guidance with proposed research, national networking, collaborations, and a peer group of junior faculty (Scholars). The NFRP NFRA will bring together established NF investigators (one Director and one Deputy Director) and early-career independent investigators (Scholars) and their Career Guides to develop successful, highly productive NF scientists and clinicians that will conduct research with the aim of lessening the clinical impact of NF1, NF2, and schwannomatosis. The NFRA is a multi-institutional interactive virtual academy platform designed to offer support to NFRA Scholars with the goal to advance innovative, high impact NF research through a collaborative and career development environment.The functioning NFRA will consist of Scholars and their Career Guides (mentors) from different institutions, and an Academy Director and Deputy Director (see Figure 1 below). The Academy Director and Deputy Director will catalyze the growth and professional development of the Scholars in collaboration with their Career Guides, assess the progress of the Scholars, and facilitate communication and collaboration among all Academy members. The Career Guide is not required to be at the same institution as the Scholar; however, if the (primary) Career Guide is from a different institution, a secondary Career Guide at the Scholar’s institution is needed. The NFRA will afford Scholars opportunities to operate in a collegial, highly dynamic, and cutting-edge center to move early-career investigators towards positions as leaders in NF conducting impactful research.During this first phase of the academy, the NFRP is offering the FY24 NFRALA funding opportunity to solicit applications for an Academy Director and Deputy Director to lead the NFRA. The Academy Director and Deputy Director (referred to as Academy Leadership) must be established NF researchers and can be at different institutions. The Academy Leadership must demonstrate a strong record of mentoring and training early-career independent investigators, a commitment to leadership, the ability to articulate methods toward research collaborations, and the ability to objectively assess the progress of all Scholars in the NFRA. An objective of the NFRA leadership team is to establish the Academy structure in its first year and in subsequent years, conduct oversight of this activity. Other objectives will include execution of research that will engage NFRA FY25 Scholars (including subsequent-year Scholars), develop tools for Scholars to enable success, and provide opportunities to broaden their knowledge in NF disorders. The leadership team will identify and offer opportunities to network with other NFRP FY25 Early Investigator Research Award recipients (and subsequent year awardees) and NFRP FY25 New Investigator Award – Early-Stage Investigator (NIA – ESI) Award recipients (and subsequent year awardees). In the second stage of the academy, the NFRP anticipates release of funding opportunities for the Scholars who will conduct their research under the guidance of the NFRA leadership team. Funding Opportunity Number: HT942524NFRPNFRALA. Assistance Listing: 12.420. Funding Instrument: CA,G. Category: ST. Award Amount: $1.5M total program funding.
The NIA Academic Leadership Career Award (K07, No Independent Clinical Trial) is a career development award from the National Institute on Aging (NIH) that supports established investigators who want to expand their expertise in aging-related research and academic leadership. Awards provide up to $150,000 per year to fund protected research and mentoring time. Eligible applicants are investigators with a doctoral degree (PhD, MD, or equivalent) who are named PD/PI on an active R01 or equivalent NIA grant, devote 25-50% full-time professional effort to the award, and are U.S. citizens or permanent residents. The application deadline is March 20, 2026.
2027 Prebys Leadership Awards is sponsored by Prebys Foundation. One-year funding recognizing leaders with a track record of promoting well-being for San Diego County. This award is part of a broader grantmaking strategy driven by community engagement to create conditions where all San Diegans are financially secure, healthy, and empowered.
NIH has awarded 74% fewer new grants than its 2021-2024 average and is roughly $1 billion behind its normal timeline, but the FY2026 money still has to go out the door before the fiscal year ends. Here is why a year-end obligation cliff is coming, who is positioned to catch it, and how applicants should prepare for a compressed Q4 award rush.
Read articleNew NIH awards have fallen 34% in 2026, NSF is running months behind, and a proposed OMB rule would let political appointees terminate grants mid-stream. The funding environment for academic research has structurally changed. Here is a clear-eyed diversification strategy for PIs, research offices, and institutions that cannot wait for the political fight to resolve.
Read articleOMB's proposed rewrite of 2 CFR Part 200 would bar political appointees from deferring to peer reviewers and require senior-appointee sign-off on every discretionary grant. NIH new awards are already down about 34% in 2026. Here is what the merit-review changes actually say, how 'Gold Standard Science' becomes a scoring lever, why R1 universities are being written out of some solicitations, and what principal investigators and research offices should do before October 1.
Read article